Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 13 chart positions in 13 markets.
By chart position
- 🇫🇷FR · Medicine#6510K to 30K
- 🇰🇷KR · Medicine#1321K to 10K
- 🇲🇽MX · Medicine#1381K to 10K
- 🇧🇷BR · Medicine#1521K to 10K
- 🇨🇱CL · Medicine#623K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
10K to 47K🎙 Weekly cadence·111 episodes·Last published 3w ago - Monthly Reach
Unique listeners across all episodes (30 days)
20K to 94K🇫🇷32%🇰🇷11%🇲🇽11%+10 more - Active Followers
Loyal subscribers who consistently listen
6K to 28K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHost
Recent guests
Recent episodes
ENP113: Clinical Practice Guideline on Central Precocious Puberty
Jun 25, 2026
17m 40s
ENP112: Osteoporosis and the SABRE Project
May 18, 2026
24m 00s
ENP111: Addressing the Endocrine Workforce Shortage
Feb 25, 2026
30m 12s
ENP110: Hypercortisolism and T2D
Jan 21, 2026
20m 03s
ENP109: Anti-Obesity Medications (CME credit available)
Jan 7, 2026
13m 15s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/25/26 | ENP113: Clinical Practice Guideline on Central Precocious Puberty | The Endocrine Society recently released a new Clinical Practice Guideline (CPG) on Central Precocious Puberty. Among its many recommendations, the CPG says some subgroups of children with precocious puberty—such as older girls with slowly progressing puberty—may not need the same level of testing or treatment.Central precocious puberty happens when a child’s brain activates puberty-related hormones too early—before age 8 years in girls and before age 9 years in boys. This early hormone signaling triggers physical changes such as breast development in girls, testicular enlargement in boys, rapid growth, and, in some cases, early menstruation.Host Aaron Lohr talks with authors of the CPG on Central Precocious Puberty: Ana Latronico, MD, PhD, Professor of Endocrinology and Metabolism at Sao Paolo University and Stephanie Roberts, MD, pediatric endocrinologist and Assistant Professor of Pediatrics at Boston Children's Hospital. | 17m 40s | ||||||
| 5/18/26 | ENP112: Osteoporosis and the SABRE Project | The U.S. Food and Drug Administration recently qualified "total hip bone mineral density" as a surrogate endpoint to support clinical trials for osteoporosis drugs. This decision will significantly impact clinical trials moving forward, as the traditional endpoint of "fracture outcomes" presented many challenges regarding sample size, duration, and cost. The change came about because of findings from the study to advance bone mineral density as a Regulatory Endpoint Project, also known as the SABRE project.What is the SABRE project, and how did it arrive at these findings? How will this decision affect the design of clinical trials and time to approval of new osteoporosis therapies? To help answer these questions and many more, Host Aaron Lohr spoke with three leaders of the SABRE Project: Dennis M. Black, PhD, professor of epidemiology and biostatistics at the University of California, San Francisco; Richard Eastell, MBChB, PhD, FRCP, FMedSci, professor of bone metabolism at the University of Sheffield, and Mary L. Bouxsein, PhD, professor of orthopedic surgery at Harvard Medical School. | 24m 00s | ||||||
| 2/25/26 | endocrine workforce shortageadvanced practice providers+4 | Sara R. MacLeod, DO, MPHShannon K. Idzik, DNP, CRNP, ANP-BC, FAANP, FAAN | Clinical Advantage: Endocrinology Certificate for Advanced Practice ProvidersEndocrine Society+1 | — | endocrinologyworkforce shortage+5 | — | 30m 12s | ||
| 1/21/26 | hypercortisolismtype 2 diabetes+3 | Vivian A. Fonseca, MDJames W. Findling, MD | Endocrine SocietyDiabetes Care+1 | — | hypercortisolismtype 2 diabetes+5 | Corcept Therapeutics Inc. | 20m 03s | ||
| 1/7/26 | anti-obesity medicationspharmacological approaches+3 | Gitanjali Srivastava, MD | Vanderbilt University Medical CenterEndocrine Society | — | anti-obesitymedications+3 | Lilly | 13m 15s | ||
| 12/17/25 | artificial intelligencerobotics+4 | Hassan M. Heshmati, MD | Endocrine SocietyEndocrinology Metabolism Consulting | — | AIrobotics+5 | — | 10m 28s | ||
| 12/3/25 | obesity medicationsGLP-1 drugs+3 | Michael Weintraub, MD | NYU Langone Division of EndocrinologyAmerican Board of Obesity Medicine | — | GLP-1obesity+5 | Lilly | 11m 49s | ||
| 11/12/25 | bariatric surgeryobesity management+3 | Katherine Hazen, MD | University of Rochester Medical Center | — | bariatric surgeryobesity+3 | — | 12m 28s | ||
| 10/29/25 | tirzepatidemenopause+3 | Maria Daniela Hurtado Andrade, MD, PhDRegina Castaneda, MD | tirzepatideMayo Clinic Florida+1 | — | tirzepatidemenopause+3 | — | 18m 36s | ||
| 10/15/25 | supplementsendocrine health+3 | Meghana Pattipati, MD | Ochsner Lafayette General Medical CenterFood and Drug Administration | San Francisco | supplementsFDA+3 | — | 10m 47s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 10/1/25 | Type 1 DiabetesImmunotherapies+3 | Desmond Schatz | Endocrine Society | — | Type 1 DiabetesImmunotherapies+3 | Abbott Diabetes Care | 23m 20s | ||
| 9/17/25 | type 1 diabetesinsulin delivery systems+3 | Grazia Aleppo, MDDiana Isaacs, PharmD | Northwestern University’s Feinberg School of MedicineCleveland Clinic | — | insulin deliverytype 1 diabetes+3 | MannKind Corp. | 31m 56s | ||
| 9/3/25 | ENP101: Papillary Thyroid Cancer | No description provided. | 9m 52s | ||||||
| 8/13/25 | ENP100: Growth Hormone Deficiency | No description provided. | 16m 35s | ||||||
| 7/9/25 | ENP99: Fracture Liaison Services | No description provided. | 19m 17s | ||||||
| 3/19/25 | ENP98: Opioids and the Endocrine System | No description provided. | 17m 13s | ||||||
| 2/12/25 | ENP97: Childhood Obesity Treatment | No description provided. | 26m 04s | ||||||
| 12/18/24 | ENP96: Automated Insulin Delivery Systems | There is a lot of interest in automated insulin delivery systems, and they were covered in depth at the Endocrine Society’s Type 1 Diabetes Fellows Series, held earlier this year. Joining host Aaron Lohr to talk about these delivery systems is Grazia Aleppo, MD, a professor of medicine at Northwestern University and a presenter at the T1D Fellows Series. Show notes are available at https://www.endocrine.org/podcast/enp96-automated-insulin-delivery-systems — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast | 19m 13s | ||||||
| 12/4/24 | ENP95: Environmental Impact on Early Female Puberty | There are plenty of studies showing that chemicals found in the environment can directly impact human health. Some new research finds that certain environmental compounds may trigger early female puberty. Joining host Aaron Lohr to talk about that research is Natalie Shaw, MD, a Lasker clinical research scholar and principal investigator of the pediatric neuroendocrinology group in the Clinical Research Branch of the National Institute of Environmental Health Sciences. Dr. Shaw and colleagues authored an article recently published in the journal Endocrinology titled, “Identification of Environmental Compounds That May Trigger Early Female Puberty by Activating Human GnRHR and KISS1R.” Show notes are available at https://www.endocrine.org/podcast/enp95-environmental-impact-on-early-female-puberty — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast | 9m 07s | ||||||
| 11/13/24 | ENP94: Update on Acromegaly | It’s been a few years, but we are here with an update on acromegaly, covering prevalence, diagnosis, traditional treatment, new therapies, and current gaps in understanding. Host Aaron Lohr talks again with Maria Fleseriu, MD, professor of medicine and professor of neurological surgery at Oregon Health & Science University School of Medicine and director of OHSU’s Pituitary Center. Dr. Fleseriu also serves on the Board of Directors of the Endocrine Society. Show notes are available at https://www.endocrine.org/podcast/enp94-update-on-acromegaly — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast | 34m 23s | ||||||
| 10/16/24 | ENP93: Prioritizing Patient Experience in Managing Diabetes | Host Aaron Lohr talks with Rita Kalyani, MD, professor of medicine at Johns Hopkins University School of Medicine and president-elect of medicine and science at the American Diabetes Association. Earlier this year, Dr. Kalyani and colleagues published a position statement in The Journal of Clinical Endocrinology & Metabolism titled, “Prioritizing Patient Experiences in the Management of Diabetes and Its Complications: An Endocrine Society Position Statement.” Show notes are available at https://www.endocrine.org/podcast/enp93-patience-experience-in-managing-diabetes — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast | 27m 28s | ||||||
| 10/2/24 | ENP92: Pheochromocytomas | In this episode, we talk about pheochromocytomas. Host Aaron Lohr talks with Nikhitha Chandrashekar, MD, who recently finished her endocrinology fellowship at University Hospitals Case Western Reserve University in Cleveland. Dr. Chandrashekar presented a case study on pheochromocytomas at ENDO 2024. Show notes are available at https://www.endocrine.org/podcast/enp92-pheochromocytomas — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast | 12m 00s | ||||||
| 9/18/24 | ENP91: Hypothyroidism and Muscle Regeneration | Our bodies typically do a remarkable job of recovering from certain injuries, and thyroid hormone signaling has an essential role to play there. But what is that process like for someone with hypothyroidism, and is there a unique role in that process for muscle stem cells? Host Aaron Lohr talks with Paola Aguiari, PhD, a senior research specialist at Children’s Hospital Los Angeles. She presented an abstract at ENDO 2024 titled, “Hypothyroidism Impairs Skeletal Muscle Regeneration After Injury.” Show notes are available at https://www.endocrine.org/podcast/enp91-hypothyroidism-and-muscle-regeneration — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast | 11m 24s | ||||||
| 9/4/24 | ENP90: Early Life Stress and Substance Use | We all know that stress leads to a number of negative outcomes. In this episode, we talk about how early life stress may influence youth substance use initiation and some endocrine factors that may be helping to drive that influence. Host Aaron Lohr talks with Alexandra M. Donovan, PhD, of the Charles R. Drew University of Medicine and Science. Dr. Donovan recently presented an abstract at ENDO 2024 titled, “Early Life Stress and Pubertal Predictors of Youth Substance Use Initiation: Does Sex Moderate the Relationship Between Early Life Stress, Puberty, and Substance Use Initiation?” Show notes are available at https://www.endocrine.org/podcast/enp90-early-life-stress-and-substance-use — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast | 25m 01s | ||||||
| 8/21/24 | ENP89: Brown Fat and Metabolic Function | In this episode, we talk about brown fat and some new discoveries in how it regulates metabolic function. Joining host Aaron Lohr is Marsel Lino, PhD, a research fellow at Joslin Diabetes Center in Boston. Dr. Lino presented an abstract at ENDO 2024 titled, “A New Layer of Endocrine Regulation: Brown Fat Secretes Exosomal MicroRNAs, Which Regulate Metabolic Functions and Distal Organs.” Show notes are available at https://www.endocrine.org/podcast/enp89-brown-fat-and-metabolic-function — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast | 15m 36s | ||||||
Showing 25 of 111
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for Endocrine News Podcast
Peaked at #62 in CL, currently #62 in CL.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| CL | — | #62 | #62 | — |
| France | — | #65 | #65 | — |
| VN | — | #106 | #106 | — |
| IS | — | #126 | #126 | — |
| HU | — | #129 | #129 | — |
| South Korea | — | #132 | #132 | — |
| Mexico | — | #138 | #138 | — |
| NG | — | #138 | #138 | — |
| TH | — | #140 | #140 | — |
| TW | — | #146 | #146 | — |
| Brazil | — | #152 | #152 | — |
| PE | — | #170 | #170 | — |
| SA | — | #173 | #173 | — |
Chart Positions
13 placements across 13 markets.
Chart Positions
13 placements across 13 markets.